SCHEMBL14964784

SCHEMBL14964784

CC1(NC(=O)C2CCN([C@H]3CCCN(C(=O)O)CC3)CC2)CCC1

nearest known ligand 0.73

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.73
LMNA P02545 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
L3MBTL3 Q96JM7 2/20 0.37
KMT2A Q03164 3/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
HRH3 Q9Y5N1 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
PKM P14618 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17254480 1.00 CHRM1 (0.73) CHRM1LMNAL3MBTL1L3MBTL3KMT2A
Htl-9936 SCHEMBL14978774 0.85 CHRM1 (1.00) CHRM1LMNAL3MBTL1KMT2AALDH1A1
Htl-9936 SCHEMBL16217938 0.85 CHRM1 (1.00) CHRM1LMNAL3MBTL1KMT2AALDH1A1
Htl-9936 SCHEMBL14964900 0.85 CHRM1 (1.00) CHRM1LMNAL3MBTL1KMT2AALDH1A1
SCHEMBL14978780 0.82 CHRM1 (0.52) CHRM1L3MBTL1L3MBTL3KMT2AALDH1A1
SCHEMBL14978880 0.82 CHRM1 (0.94) CHRM1LMNAL3MBTL1ALDH1A1GAA
SCHEMBL20153427 0.81 CHRM1 (0.53) CHRM1LMNAHRH3
SCHEMBL14978907 0.81 CHRM1 (0.93) CHRM1LMNAL3MBTL1KMT2AALDH1A1
SCHEMBL15618631 0.80 CHRM1 (0.52) CHRM1HRH3
SCHEMBL15618629 0.80 CHRM1 (0.52) CHRM1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US claimed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US claimed
US-10413553-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-09-17 US claimed
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2018-06-07 US claimed
EP-2780015-B1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2017-01-04 EP claimed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US claimed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US claimed
EP-2780015-A1 MUSCARINIC M1 RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2014-09-24 EP claimed
WO-2013072705-A1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2013-05-23 WO claimed
US-11793817-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2023-10-24 US disclosed
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2021-11-18 US disclosed
US-10973832-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2021-04-13 US disclosed
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2020-08-13 US disclosed
US-10413553-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-09-17 US disclosed
EP-2780015-B1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LTD (GB) 2017-01-04 EP disclosed
US-20160068508-A1 Muscarinic M1 Receptor Agonists NXERA PHARMA UK LIMITED (GB) 2016-03-10 US disclosed
US-9187451-B2 Muscarinic M1 receptor agonists HEPTARES THERAPEUTICS LIMITED (GB) 2015-11-17 US disclosed
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS NXERA PHARMA UK LIMITED (GB) 2014-11-06 US disclosed
EP-2780015-A1 MUSCARINIC M1 RECEPTOR AGONISTS Heptares Therapeutics Limited (GB) 2014-09-24 EP disclosed
WO-2013072705-A1 MUSCARINIC M1 RECEPTOR AGONISTS HEPTARES THERAPEUTICS LIMITED (GB) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140329803-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-20180153900-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-20160068508-A1 Muscarinic M1 Receptor Agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-20200253982-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-20210353637-A1 MUSCARINIC M1 RECEPTOR AGONISTS CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-10973832-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-10413553-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885
US-11793817-B2 Muscarinic M1 receptor agonists CHRM1, CHRM2, CHRM3 CHRM1 1/4885LMNA 2580/4885L3MBTL1 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.